
TriGemX Bio, formerly known as Kallyope, has raised $94 million in new funding to support the clinical development of its lead migraine treatment.
The financing was co-led by The Column Group, TCGX, and Viking Global Investors, with additional investors also participating.
TriGemX Bio plans to use the funding to advance elismetrep, an oral TRPM8 channel blocker that is currently being tested in Phase 3 clinical trials for the acute treatment of migraine. The company expects results from its first Phase 3 trial in mid-2027.
Along with the financing, the company has relaunched under the name TriGemX Bio and appointed new leadership. Jeff Goater has joined as Chief Executive Officer, while Aninda Katragadda has been appointed Chief Financial Officer. They will work with Chief Medical Officer Brett Lauring, M.D., Ph.D.
“Today’s announcement represents the start of an exciting new chapter for the company,” said Jeff Goater, CEO of TriGemX Bio. “Migraine is one of the most common neurological diseases, and a meaningful percentage of affected patients do not achieve adequate relief from existing therapies. The impact on quality of life for migraine sufferers can be severe, and we believe elismetrep will be a valuable addition to the physician armamentarium to treat this disease. I am eager to work alongside the entire TriGemX Bio team to advance this important new medicine.”
TriGemX Bio is developing elismetrep as a potential new treatment option for migraine. The company says its approach focuses on the TRPM8 channel, which is expressed in the trigeminal ganglion, a neural structure associated with migraine.
“Our Phase 2b data, as well as the advantages of our new liquid-filled soft gel formulation reinforce the differentiated profile of elismetrep as a promising investigational therapy for the acute treatment of migraine,” said Brett Lauring, M.D., Ph.D., CMO of TriGemX Bio. “Furthermore, TRPM8 is a mechanistically distinct therapeutic target compared to targets of all other current migraine medicines. Our Phase 3 program for elismetrep is well underway and we look forward to sharing initial clinical results in mid-2027.”
Cariad Chester, Managing Partner at TCGX, added: “We are excited to support TriGemX Bio and the pivotal Phase 3 trials of elismetrep. Despite the significant advances enabled by CGRP-targeted therapies, fewer than a third of patients achieve adequate control of their migraine symptoms, underscoring the substantial need for new treatment options. We believe elismetrep has the potential to address this need and play a foundational role in the treatment of migraine. The TriGemX team has deep expertise in migraine biology and clinical development, positioning the company for success as we rapidly advance elismetrep through Phase 3 trials and towards FDA approval.” As part of the financing, Cariad Chester joined the Board of Directors of TriGemX Bio.
The company is targeting a large global patient population, with migraine affecting approximately one billion people worldwide.
The new funding will support the ongoing Phase 3 development program and the company’s efforts to advance elismetrep toward potential regulatory milestones.